Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$3.36 USD
+0.05 (1.51%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $3.37 +0.01 (0.30%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
EDIT 3.36 +0.05(1.51%)
Will EDIT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EDIT
Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
Illumina (ILMN) Q2 Earnings and Revenues Top Estimates
Other News for EDIT
Warning: EDIT is at high risk of performing badly
Warning: EDIT is at high risk of performing badly
Warning: EDIT is at high risk of performing badly
Warning: EDIT is at high risk of performing badly
Warning: EDIT is at high risk of performing badly